BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27902464)

  • 1. Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage.
    Wang X; Liu F; Qin X; Huang T; Huang B; Zhang Y; Jiang B
    Aging (Albany NY); 2016 Nov; 8(11):2790-2798. PubMed ID: 27902464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A.
    Xu BH; Li XX; Yang Y; Zhang MY; Rao HL; Wang HY; Zheng XF
    Oncotarget; 2015 Aug; 6(25):20813-28. PubMed ID: 26308575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rab1A promotes proliferation and migration abilities via regulation of the HER2/AKT-independent mTOR/S6K1 pathway in colorectal cancer.
    Cheng Z; Shao X; Xu M; Wang J; Kuai X; Zhang L; Wu J; Zhou C; Mao J
    Oncol Rep; 2019 May; 41(5):2717-2728. PubMed ID: 30896866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway.
    Li Z; Li Y; Jia Y; Ding B; Yu J
    Arch Biochem Biophys; 2020 May; 685():108352. PubMed ID: 32240637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression analysis and implication of Rab1A in gastrointestinal relevant tumor.
    Xu M; Shao X; Kuai X; Zhang L; Zhou C; Cheng Z
    Sci Rep; 2019 Sep; 9(1):13384. PubMed ID: 31527621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of long non-coding RNA RAB1A-2 induces FGF1 expression worsening lung cancer prognosis.
    Wu D; Yang B; Chen J; Xiong H; Li Y; Pan Z; Cao Y; Chen J; Li T; Zhou S; Ling X; Wei Y; Li G; Zhou Y; Qiu F; Yang L; Lu J
    Cancer Lett; 2018 Dec; 438():116-125. PubMed ID: 30217564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant expression of Rab1A and its prognostic significance in human colorectal cancer.
    Wang ZK; Cheng ZW; Chen SJ; Zhu XG; Gu YP; Yang XD; Sun L; Liu WT; Zhang YJ; Yuan JF; Tian KJ; Yao YZ; He SB
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4509-4517. PubMed ID: 30058685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rab1A promotes cell proliferation and migration by upregulating Gli1 in colorectal cancer.
    Peng C; Li X; Ye Z; Wu W
    Sci Rep; 2021 Aug; 11(1):16243. PubMed ID: 34376787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More expression of BDNF associates with lung squamous cell carcinoma and is critical to the proliferation and invasion of lung cancer cells.
    Zhang SY; Hui LP; Li CY; Gao J; Cui ZS; Qiu XS
    BMC Cancer; 2016 Feb; 16():171. PubMed ID: 26926340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rab1A is an mTORC1 activator and a colorectal oncogene.
    Thomas JD; Zhang YJ; Wei YH; Cho JH; Morris LE; Wang HY; Zheng XF
    Cancer Cell; 2014 Nov; 26(5):754-69. PubMed ID: 25446900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
    Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
    J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of RAB1A suppresses epithelial-mesenchymal transition and proliferation of triple-negative breast cancer cells.
    Xu H; Qian M; Zhao B; Wu C; Maskey N; Song H; Li D; Song J; Hua K; Fang L
    Oncol Rep; 2017 Mar; 37(3):1619-1626. PubMed ID: 28184936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAB1A regulates glioma cellular proliferation and invasion via the mTOR signaling pathway and epithelial-mesenchymal transition.
    Ren B; Wang L; Nan Y; Liu T; Zhao L; Ma H; Li J; Zhang Y; Ren X
    Future Oncol; 2021 Aug; 17(24):3203-3216. PubMed ID: 33947216
    [No Abstract]   [Full Text] [Related]  

  • 15. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma.
    Gout S; Brambilla E; Boudria A; Drissi R; Lantuejoul S; Gazzeri S; Eymin B
    PLoS One; 2012; 7(10):e46539. PubMed ID: 23071587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion.
    Marwitz S; Depner S; Dvornikov D; Merkle R; Szczygieł M; Müller-Decker K; Lucarelli P; Wäsch M; Mairbäurl H; Rabe KF; Kugler C; Vollmer E; Reck M; Scheufele S; Kröger M; Ammerpohl O; Siebert R; Goldmann T; Klingmüller U
    Cancer Res; 2016 Jul; 76(13):3785-801. PubMed ID: 27197161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.
    Matsuda Y; Yamamoto T; Kudo M; Kawahara K; Kawamoto M; Nakajima Y; Koizumi K; Nakazawa N; Ishiwata T; Naito Z
    Int J Oncol; 2008 Dec; 33(6):1177-85. PubMed ID: 19020750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.